VOLUME 23 | NUMBER 9 | SEPTEMBER 2017 nature medicine a r t i c l e s d-mannose is a C-2 epimer of glucose and occurs naturally in many plants and fruits, especially cranberries. Glucose is known to have central roles in energy generation, storage, and regulation in the cell, as well as pathogenic roles in diabetes and obesity. However, d-mannose, which has a physiological blood concentration less than one-fiftieth of that of glucose 1 , has not received much attention. Nevertheless, d-mannose is important in the glycosylation of certain proteins 2,3 . d-mannose has been reported to be mainly beneficial in human disease states. For example, a d-mannose supplement has been shown to be an effective therapy for congenital disorders of glycosylation type Ib 2,4 . It has also been used as a non-antibiotic treatment for bacterial urinary tract infection in animals 5 and humans 6 , with a proposed mechanism of binding to the type 1 pili of enteric bacteria and thereby blocking their adhesion to uroepithelial cells 7 . It is well established that glucose has a vital role in immune cell activity, especially in T cell activation and differentiation [8] [9] [10] . However, it is unknown whether d-mannose has any effect on T cells and immune responses. Here we show that oral administration of d-mannose suppressed immunopathology in models of autoimmune diabetes and airway inflammation. d-mannose was able to induce the generation of T reg cells from naive CD4 + T cells by promoting activation of the latent form of TGF-β. d-mannose-mediated TGF-β activation required integrin α v β 8 and reactive oxygen species (ROS) in T cells. Moreover, we observed that d-mannose decreased glycolysis but increased fatty acid oxidation in T cells. We conclude that collectively, these actions drive immune responses toward an immunoregulatory phenotype and subsequent tolerance.
a r t i c l e s d-mannose is a C-2 epimer of glucose and occurs naturally in many plants and fruits, especially cranberries. Glucose is known to have central roles in energy generation, storage, and regulation in the cell, as well as pathogenic roles in diabetes and obesity. However, d-mannose, which has a physiological blood concentration less than one-fiftieth of that of glucose 1 , has not received much attention. Nevertheless, d-mannose is important in the glycosylation of certain proteins 2, 3 . d-mannose has been reported to be mainly beneficial in human disease states. For example, a d-mannose supplement has been shown to be an effective therapy for congenital disorders of glycosylation type Ib 2, 4 . It has also been used as a non-antibiotic treatment for bacterial urinary tract infection in animals 5 and humans 6 , with a proposed mechanism of binding to the type 1 pili of enteric bacteria and thereby blocking their adhesion to uroepithelial cells 7 . It is well established that glucose has a vital role in immune cell activity, especially in T cell activation and differentiation [8] [9] [10] . However, it is unknown whether d-mannose has any effect on T cells and immune responses. Here we show that oral administration of d-mannose suppressed immunopathology in models of autoimmune diabetes and airway inflammation. d-mannose was able to induce the generation of T reg cells from naive CD4 + T cells by promoting activation of the latent form of TGF-β. d-mannose-mediated TGF-β activation required integrin α v β 8 and reactive oxygen species (ROS) in T cells. Moreover, we observed that d-mannose decreased glycolysis but increased fatty acid oxidation in T cells. We conclude that collectively, these actions drive immune responses toward an immunoregulatory phenotype and subsequent tolerance.
RESULTS d-mannose induces T reg cells
To determine whether d-mannose has a role in T cell activation, we cultured naive mouse CD4 + CD25 − T cells in medium supplemented with mannose or other sugars in the presence of T cell receptor (TCR) stimulation. d-mannose affected neither the T-cell-activationassociated markers nor apoptosis ( Supplementary Fig. 1a,b) . However, d-mannose suppressed T cell proliferation (Fig. 1a) , resulting in lower absolute cell numbers after 48-72 h of culture. In d-mannose-treated T cells, levels of mRNAs associated with type 1 helper T cells (T H 1 cells) (Ifng and Il2), type 2 helper T cells (T H 2 cells) (Il4 and Il13) and Il6 were lower than in control cells, yet amounts of Il17a and Il10 mRNA remained unchanged ( Supplementary Fig. 2a-g ). d-mannose induced the generation of significantly more Foxp3 + T reg cells and higher amounts of Foxp3 mRNA from naive CD4 + CD25 − T cells compared with the control medium ( Fig. 1b-d) , whereas the absolute number of CD4 + Foxp3 − non-T reg cells among d-mannosetreated cells was lower at 72 h after culture (Supplementary Fig. 2h) . Similarly, numbers of T reg cells were higher in d-mannose-treated TCR-stimulated cultures of naive CD4 + CD25 − GFP − (Foxp3 − ) T cells isolated from transgenic mice expressing Foxp3-GFP (Fig. 1e) . The induction of T reg cells was dependent on the dose of d-mannose, and similar doses of glucose did not increase T reg cell generation (Supplementary Fig. 3a) . Similarly, stimulation of naive CD4 + T cells by d-mannose in cultures with soluble anti-CD3 and splenic antigenpresenting cells (APCs) also significantly increased T reg cell generation (Fig. 1f, Supplementary Fig. 3b ). Thus, d-mannose specifically induced Foxp3 expression and T reg cell fate in naive T cells in vitro.
Extending this finding to antigen-specific stimulation, d-mannose converted naive CD4 + CD25 − KJ1-26 + TCR-transgenic T cells into Foxp3 + T reg cells in response to their cognate antigen OVAp [323] [324] [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] (Fig. 1g, Supplementary Fig. 3c ). Importantly, d-mannose induced T reg cells in vivo. We administered d-mannose in drinking water to BALB/cJ mice for 2 weeks, and then subjected the mice to adoptive transfer of KJ1-26 + CD4 + CD25 − naive T cells and ovalbumin to induce T reg cell generation in a mucosal T reg cell induction model 11, 12 ( Supplementary Fig. 4a ). d-mannose significantly increased the frequency of T reg cells in transferred TCR-transgenic T cells in response to ovalbumin in Peyer's patches, mesenteric lymph nodes, lamina propria and spleen (Fig. 1h) without affecting the host T reg cell frequency (Supplementary Fig. 4b ). However, there was no significant decrease in the number of IFN-γ + and IL-17A + T cells among transferred DO11.10 TCR-transgenic T cells (Supplementary Fig. 4c,d) . Taken together, our findings show that d-mannose consistently promoted T reg cell differentiation.
d-mannose-induced T reg cells exhibit suppressive capacity
We next investigated the function of T reg cells induced by d-mannose. In vitro, d-mannose-induced T reg cells potently suppressed the proliferation of naive CD4 + T cells similarly to TGF-β1-induced T reg cells and freshly isolated CD4 + CD25 + GFP + T reg cells from the spleens of Foxp3-GFP transgenic mice in vitro 13 ( Supplementary  Fig. 5a ). To investigate the immunosuppressive function of mannose-induced T reg cells in vivo, we used a T-cell-transfer model of colitis 14 . We transferred CD4 + CD45RB hi T cells into Rag1 −/− mice, with or without cotransfer of d-mannose-induced T reg cells, TGF-β1-induced T reg cells or CD4 + CD25 + GFP + T reg cells from Foxp3-GFP mice. All three types of T reg cells effectively prevented weight loss and suppressed colon inflammation (Supplementary Fig. 5b,c) . In addition, d-mannose-induced T reg cells exhibited a DNA-methylation pattern similar to that of TGF-β1-induced T reg cells (data not shown) 15 . These results suggest that mannose-induced T reg cells possess suppressive capacity. As TGF-β signaling is critical for T reg cell generation [16] [17] [18] , we investigated the role of TGF-β in this process. We first determined that d-mannose treatment enhanced TGF-β signal transduction, as demonstrated by increased expression of TGF-β-inducible 19, 20 Smad7 and Fos mRNAs (Supplementary Fig. 6a,b) . Pharmacological or antibody-mediated blockade of TGF-β signaling completely abrogated the increase in Foxp3 mRNA expression and the consequent increase in the number of T reg cells induced by d-mannose in wild-type naive CD4 + T cells (Fig. 2a,b, Supplementary Fig. 6c ) and in naive KJ1-26 + CD4 + T cells cultured with OVAp 323-339 (Supplementary Fig. 6d ). Interestingly, naive CD4 + CD25 − T cells from mice deficient in TGF-β receptor I (Tgfbr1 f/f CD4-Cre) 18, 21 or II (Tgfbr2 f/f ER-Cre, plus tamoxifen treatment) 22 did not differentiate into T reg cells at all in response to d-mannose stimulation (Fig. 2c,d) . Consistently, CD4 + naive T cells deficient in Smad3 (Smad3 −/− ) 23 , a critical mediator downstream of TGF-β 24, 25 , showed a significant reduction in amounts of d-mannoseinduced T reg cells (Supplementary Fig. 6e ; P < 0.01). TGF-β signaling was also required for d-mannose-induced T reg cell generation in vivo ( Supplementary Fig. 7a ), as injection of anti-TGF-β abolished the increase in the number of T reg cells among adoptively transferred KJ1-26 + CD4 + T cells induced by d-mannose in BALB/cJ mice (Fig. 2e) , without affecting the frequency of host T reg cells (Supplementary Fig. 7b ).
Thus, we conclude that TGF-β signaling is required for d-mannose induction of T reg cells in culture and in vivo. We also investigated whether d-mannose promotes the generation of human T reg cells. d-mannose treatment indeed significantly upregulated the frequency of human CD4 + CD25 hi Foxp3 + T reg cells 26 compared with the control condition (Fig. 2f) . Blockade of TGF-β signaling significantly reduced this effect (Fig. 2f) . d-mannose-induced human T reg cells had suppressive activity toward normal human CD4 + T cell proliferation, similarly to TGF-β1-induced T reg cells in standard suppression assays in vitro 13 (Supplementary Fig. 8a,b) . Thus, as in mouse T cells, d-mannose also drove T reg cell generation in human naive CD4 + T cells via a TGF-β-dependent mechanism.
We next determined which aspects of TGF-β signaling 19, 27, 28 are influenced by d-mannose. d-mannose did not change the levels of Tgfb1 mRNA or total TGF-β1 protein compared with pre-supplementation levels, which suggested that there was no effect on TGF-β transcription or protein synthesis (Supplementary Fig. 9a ). d-mannose treatment in the presence of TCR stimulation slightly upregulated the expression of mRNA for TGF-β receptor I (TβRI) and II (TβRII) compared with TCR stimulation alone ( Supplementary Fig. 9b,c) .
TGF-β is produced as a latent form in complex with latent associated protein (LAP) 28, 29 . d-mannose increased T reg cell numbers only slightly in the presence of bioactive TGF-β1 ( Supplementary Fig. 9d ), Oil Tamoxifen
Med Latent TGF-β1 which suggests that increased expression of the TGF-β receptors is not the main mechanism of D-mannose action. In contrast, d-mannose significantly potentiated T reg cell generation in cultures supplemented with LAP-TGF-β1 ( Fig. 2b-d,g ). This was further shown by significant increases in amounts of Foxp3 mRNA ( Fig. 6c,d) . Moreover, when we cultured naive CD4 + CD25 − T cells in X-vivo-20 medium, which does not contain TGF-β, as it is serum-free, d-mannose promoted T reg cell generation only in the presence of LAP-TGF-β1 ( Supplementary Fig. 9e,f) .
To confirm that d-mannose-mediated activation of LAP-TGF-β1 enhanced TGF-β signal transduction, we determined that the amount of phospho-Smad3 increased in T cells in response to treatment with d-mannose and LAP-TGF-β1 (Supplementary Fig. 9g) . Importantly, the d-mannose-and LAP-TGF-β1-mediated increase in the number of T reg cells was completely abolished when TGF-β signaling was blocked (Fig. 2g) , or when naive CD4 + T cells lacked either TβRI or TβRII expression (Fig. 2c,d) . Naive Smad3 −/− CD4 + T cells also showed a 2.5-fold decrease in numbers of d-mannose/LAP-TGF-β1 induced T reg cells (Supplementary Fig. 6e ). Finally, we investigated whether d-mannose could induce substantial numbers of T reg cells at physiologically relevant concentrations (~1 mM), by culturing naive CD4 + T cells with LAP-TGF-β1 in vitro in the presence of different doses of d-mannose (Supplementary Fig. 9h ). Taken together, our findings suggest that d-mannose induces the generation of T reg cells by augmenting TGF-β signaling via activation of latent TGF-β.
Integrin a v b 8 and ROS are required for d-mannose-induced T reg cell generation Several molecules have been suggested to be involved in TGF-β activation in immune cells, including integrin α v β 8 (encoded by Itgav and Itgb8 subunits) [30] [31] [32] and reactive oxygen species (ROS) 33, 34 . d-mannose stimulation increased the expression of Itgav and Itgb8 mRNA in naive CD4 + T cells (Fig. 3a,b) compared with that in unstimulated T cells. We then activated naive CD4 + CD25 − integrin β 8 -deficient T cells 32 in vitro in the presence of d-mannose and observed that the loss of integrin β 8 significantly reduced d-mannose-induced T reg cell generation even in the absence of exogenous LAP-TGF-β1 (Fig. 3c) . When we added exogenous LAP-TGF-β1 to the cultures, integrin β 8 -deficient T cells showed a significant defect in T reg cell generation (~50% decrease) in response to d-mannose (Fig. 3c) , thus suggesting that integrin β 8 has an important role in mediating TGF-β1 activation induced by d-mannose.
As the action of integrin β 8 could not totally account for all TGF-β1 activation, we also determined that ROS participated in TGF-β1 activation by d-mannose. ROS can be produced in T cells after TCR activation 35, 36 . We found that d-mannose treatment increased ROS production in T cells compared with TCR stimulation alone (Fig. 3d) . Importantly, blockade of ROS activity by N-acetyl-L-cysteine (NAC) 37 also significantly reduced numbers of d-mannose-induced T reg cells in the presence of LAP-TGF-β1 (Fig. 3c) . Notably, neutralization of ROS by NAC in integrin β 8 -deficient naive CD4 + T cells further decreased T reg cell generation induced by d-mannose by 70-80% (Fig. 3c) , suggesting a combinatorial function involving the integrin and ROS pathways. Thus, the integrin α v β 8 and ROS pathways can be assumed to have independent yet complementary roles in d-mannose-mediated TGF-β1 activation and consequent T reg cell generation in vitro.
d-mannose increases fatty acid oxidation We next investigated how d-mannose induces ROS. After TCR activation, naive T cells switch from oxidative phosphorylation to aerobic glycolysis 8 . We hypothesized that as d-mannose and d-glucose increased ROS production to similar levels ( Supplementary Fig. 10a ), d-mannose might also upregulate glycolysis in T cells. To test this, we cultured naive T cells in sugarless media supplemented with pyruvate and L-glutamine and measured their extracellular acidification rate in response to d-glucose or d-mannose. Unexpectedly, cells supplemented with d-mannose had a markedly lower acidification rate at maximal respiration compared with cells cultured in d-glucose (Supplementary Fig. 10b ). This indicated a reduced capacity to utilize glycolysis in response to stress.
As fatty acid oxidation (FAO) can generate ROS 38,39 , we hypothesized that d-mannose might induce ROS via that pathway. To investigate this, we measured the oxygen consumption rate (OCR) of naive CD4 + T cells cultured in either d-mannose or d-glucose. Although both oxidative phosphorylation and FAO occur in the mitochondria and contribute to the OCR, only FAO is affected by etomoxir, an inhibitor of CPT1, the enzyme responsible for the transport of fatty acids into mitochondria. Cells cultured in d-mannose had significantly higher (P < 0.01) OCRs (~25%) at maximal respiration than Fig. 10c ). However, simultaneous treatment with etomoxir led to a decrease in the OCR of mannose-cultured cells, whereas no such decrease was observed in etomoxir-treated glucose-cultured cells, indicating that a portion of the OCR in mannose-treated cells can be attributed to active FAO, especially where spare capacity is required (e.g., during proliferation) (Supplementary Fig. 10c ). The greater utilization of FAO in mannose-cultured T cells might explain the higher ROS levels observed in these cells, although how d-mannose-induced FAO drives ROS production remains unknown. Nonetheless, the increased amount of ROS contributes to the activation of latent TGF-β during the generation of T reg cells. Thus, we suggest that T cells cultured with d-mannose preferentially use FAO, which can result in higher ROS levels and thus greater TGF-β activation.
d-mannose suppresses type 1 diabetes in NOD mice We next determined whether d-mannose has beneficial effects in autoimmunity, using as a type 1 diabetes model non-obese diabetic (NOD) mice, in which pathology involves T reg cell defects 40 . NOD mice received d-mannose in their drinking water starting at 7.5 weeks of age, when the mice are considered prediabetic, and at which point the inflammatory process has just been initiated but blood glucose levels are still within the normal range 40 (Supplementary Fig. 11a ).
As expected, control (non-d-mannose-treated) NOD mice started to develop diabetes at about 12-13 weeks of age, and 80-90% became diabetic by the age of 23 weeks (Fig. 4a) . However, most of the NOD mice supplemented with d-mannose were diabetes-free through 23 weeks of age (Fig. 4a) . Consistent with protection from diabetes, d-mannose-treated mice showed considerably less insulitis and more preserved islets compared with controls (Fig. 4b,c) .
We examined the T cell responses of these mice at 13-14 weeks of age, when the untreated NOD mice were expected to start to develop hyperglycemia. The frequency of CD4 + CD25 + Foxp3 + T reg cells in the spleen and pancreatic draining lymph nodes (DLNs) was significantly higher in d-mannose-treated mice than in untreated mice (Fig. 4d) . In contrast, the frequencies of CD4 + IFN-γ + and CD8 + IFN-γ + T cells were lower in the spleens of the NOD mice supplemented with d-mannose (Fig. 4e,f) . In addition, numbers of CD4 + IL-4 + (T H 2) cells were also lower in the spleens of d-mannose-treated mice (Supplementary Fig. 11b ), whereas the frequencies of CD4 + IL-17A + (T H 17) and CD4 + IL-10 + T cells were unchanged compared with those in controls (Supplementary Fig. 11b ). In the pancreas, the frequency of CD4 + Foxp3 + T reg cells was increased and that of IFN-γ-producing CD4 + and CD8 + T cells was decreased in d-mannose-treated mice compared with controls (Supplementary Fig. 11c ). In addition to the ex vivo analysis of T cells, we also examined autoantigen-specific T cell cytokine production in splenic T cells in response to restimulation with a pancreas-derived peptide, GAD65. GAD65-specific T cell IFN-γ production was significantly reduced in the spleens of d-mannose-treated NOD mice (Fig. 4g) , whereas GAD65-specific IL-17 and IL-10 production did not change compared with the levels in control mice (Supplementary Fig. 11d) . Moreover, treatment of NOD mice with d-mannose once they had reached prediabetic blood glucose levels of 140-160 mg/dL (Supplementary Fig. 11e ) or new-onset diabetic levels of 200-230 mg/dL (refs. 41, 42) (Supplementary Fig. 12a ) suppressed the progression of diabetes (Fig. 4h-k, Supplementary Fig. 12b-d) . Similar to what we observed in the treated prediabetic NOD mice, d-mannose treatment at these stages also significantly increased the frequency of T reg cells and decreased the frequencies of T H 1 cells and CD8 + IFN-γ + T cells in the pancreas compared with those in control mice ( Fig. 4h-k, Supplementary Fig. 12 ).
To study whether the increase in the amount of T reg cells is involved in d-mannose-treatment-mediated suppression of diabetes, we depleted CD4 + CD25 + T reg cells with anti-CD25 in d-mannose-treated and untreated NOD mice (Supplementary Fig. 13a ). We first confirmed that anti-CD25 sufficiently depleted T reg cell populations in NOD mice (~50% depletion of total CD4 + Foxp3 + T reg cells; 70-80% depletion of CD4 + CD25 + Foxp3 + T reg cells). In NOD mice, anti-CD25 did not significantly change the frequency of CD25 + Foxp3 − effector cells. We found that depletion of CD4 + CD25 + T reg cells abolished the protective effects of d-mannose on diabetes development, and the same anti-CD25 treatment at that stage slightly affected the development of diabetes in untreated NOD mice (Fig. 5a) . Consistently, administration of anti-CD25 reversed the d-mannose-mediated decrease in insulitis and preservation of the total number of islets in the pancreas (Fig. 5b,c) . In the spleen and DLNs of d-mannosetreated mice, the increase in the frequency of CD4 + CD25 + Foxp3 + T reg cells was abolished by anti-CD25 treatment (Fig. 5d) . Consequently, the increased ratios of CD25 + Foxp3 + T reg cells to CD4 + IFN-γ + or CD8 + IFN-γ + T cells in d-mannose-treated mice were eliminated after anti-CD25 treatment (Fig. 5e,f) . Furthermore, we validated a role of T reg cells in d-mannose-mediated suppression of diabetes in NODFoxp3 DTR mice treated with diphtheria toxin (data not shown). These data suggest that the increased T reg cell population is involved in d-mannose-treatment-mediated suppression of diabetes. Lastly, neutralization of endogenous TGF-β with anti-TGF-β ( Supplementary  Fig. 13b ) in d-mannose-treated NOD mice also abrogated the suppressive effects of d-mannose on diabetes, with abolishment of the increase in T reg cell numbers (Fig. 5g,h, Supplementary Fig. 13c,d ). Together these data indicate that d-mannose suppresses the immunopathology of autoimmune diabetes in NOD mice, and that T reg cells and TGF-β are involved in this process.
d-mannose prevents and suppresses ovalbumin-induced airway inflammation
The success of d-mannose supplementation in suppressing diabetes development in NOD mice encouraged us to investigate whether mannose-mediated T reg cell generation has broader effects in immunopathology. We next tested d-mannose function in a model of lung airway inflammation. We used an ovalbumin-induced airway inflammation model in which KJ1-26 + CD4 + CD25 − naive T cells isolated from DO11.10 TCR-transgenic Rag2 −/− mice were adoptively transferred into BALB/cJ mice [43] [44] [45] . This system allowed us to assess the conversion of KJ1-26 + CD4 + CD25 − naive T cells to T reg cells in vivo in the airway inflammation model in response to d-mannose administration (Supplementary Fig. 14a) . Indeed, we found that d-mannose treatment prevented the development of airway inflammation in the lungs, as demonstrated by considerably less infiltration of inflammatory cells and reduced mucus production in the airways compared with that in control mice (Fig. 6a,b) . The bronchoalveolar lavage fluid of d-mannose-treated mice had significantly fewer inflammatory leukocytes, particularly eosinophils, compared with that of control mice (Fig. 6c) . In accordance with the diminished inflammation in their lungs, d-mannose-treated mice showed significantly lower frequencies of IL-13 + T cells and substantially reduced frequencies of IL-4 + KJ1-26 + T cells in the lungs and the peripheral lymphoid tissues compared with control mice (Fig. 6d,e) . Intriguingly, there were also lower frequencies of IL-13 + and IL-4 + T H 2 cells among the nontransgenic CD4 + host T cells in the lungs of mice treated with d-mannose compared with untreated control mice, although there were no changes in their peripheral lymphoid tissues ( Supplementary  Fig. 14b,c) . Importantly, d-mannose treatment resulted in a significant increase in the number of KJ1-26 + CD4 + Foxp3 + T reg cells in the lungs as well as in the spleen and DLNs compared with those of control mice (Fig. 6f) . However, we observed a decrease in the frequency of nontransgenic CD4 + Foxp3 + host T reg cells in the lungs and peripheral lymphoid tissues in the same d-mannose-treated mice compared with those in controls (Supplementary Fig. 14d ).
To investigate whether d-mannose can be effective in a clinically relevant setting, we first induced airway inflammation in the mice and then treated them with d-mannose in drinking water ( Supplementary  Fig. 15a) . We found that d-mannose treatment significantly ameliorated airway inflammation (Fig. 6g-i) . This was accompanied by decreased frequencies of IL-4 + and IL-13 + T cells and increased frequencies of Foxp3 + T reg cells within the population of transferred KJ1-26 + CD4 + T cells in the lungs, DLNs and spleen compared with those in control mice (Fig. 6j-l) . The frequencies of IL-4 + and IL-13 + T cells among the nontransgenic host CD4 + T cells in the lungs were also significantly decreased (P < 0.05), but the frequency of the host T reg cells was not changed in the same d-mannose-treated mice ( Supplementary  Fig. 15b-d) . These results collectively show that d-mannose supplementation induces antigen-specific T reg cells and suppresses the TGF-β is essential for the generation of Foxp3 + T reg cells from naive CD4 + T cells [16] [17] [18] , and we show that enhanced TGF-β signaling is an underlying mechanism that promotes d-mannose-induced T reg cell generation. Indeed, blockade of TGF-β signaling in vitro and in vivo abolished d-mannose-induced T reg cell generation. Further mechanistic studies showed that the activation of latent TGF-β, rather than TGF-β protein synthesis, was key to the increased TGF-β signaling brought about by d-mannose in T cells. Moreover, our finding that the addition of exogenous LAP-TGF-β1 but not of active TGF-β1 enhanced T reg cell generation in d-mannose-treated T cells further supports this conclusion, as LAP-TGF-β1 cannot signal without activation. A previous study showed that a high concentration of glucose (for example, >25 mM) can activate TGF-β and may be involved in the growth of epithelial and mesenchymal cells 46 . Our results here show that 5-50 mM glucose did not induce significant T reg cell generation in T cells in the absence of exogenous LAP-TGF-β1. The detailed mechanism remains unknown, but it is possible that a high concentration of glucose induces T cell activation through glycolysis and increased production of inflammatory cytokines such as IFN-γ, IL-6 and IL- 4 (refs. 8,47) , which may antagonize Foxp3 induction by TGF-β. Indeed, we noticed that glucose treatment of TCR-stimulated naive CD4 + T cells in the presence of anti-IL-4, anti-IL-6 and anti-IFN-γ increased the frequency of T reg cells compared with control antibody treatment, although the increase was still far less than that observed in d-mannose-induced T reg cells.
We then determined that d-mannose-mediated TGF-β activation and T reg cell generation involved integrin α v β 8 and ROS [30] [31] [32] 48 . Supporting this conclusion are the findings that d-mannose increased integrin α v β 8 expression and ROS production in T cells, and that deletion of Itgb8 and/or blockade of ROS activity abolished the majority of d-mannose-induced T reg cell generation. The exact mechanisms underlying d-mannose-driven ROS production remain unknown, but they may involve increased FAO that also produces more ROS, as d-mannose increases FAO in T cells. The finding that d-mannose suppressed glycolysis in T cells may provide an explanation for the decreased T cell proliferation and IFN-γ production observed after d-mannose treatment, as these are canonical features of glycolysis induced by TCR stimulation. Notably, although both glucose and mannose can upregulate ROS, only d-mannose, and not the corresponding amount of glucose, induced Foxp3. Nevertheless, further molecular details on this pathway are required. However, one possibility might be that d-mannose but not glucose upregulates integrin α v β 8 expression. Although we cannot currently conclude that this is the case, our data strongly suggest that d-mannose upregulation of integrin α v β 8 is an important factor in the difference.
Importantly, d-mannose effectively suppressed autoimmune type 1 diabetes and airway inflammation in mice. Oral supplementation with d-mannose in NOD mice before they developed hyperglycemia affected diabetes development in those mice. In addition, oral administration of d-mannose was able to block the progress of diabetes even in new-onset diabetic NOD mice. Similarly, oral administration of d-mannose also prevented and suppressed airway inflammation in the lungs. Of note, long-term supplementation with d-mannose had no obvious side-effects in the NOD mice-a finding that might have implications for the development of a similar clinical therapy for type 1 diabetes in humans 49 . Although a systemic increase in the amount of active TGF-β might have potential effects on the fibrotic response 50 , the fact that d-mannose was well tolerated in mice here suggests that TGF-β activation might have local effects on surrounding T cells, which are less likely to cause a notable fibrotic response. More long-term studies could help rule out this possibility. Moreover, given that d-mannose can activate TGF-β and promote T reg cell generation, whether it affects other disease conditions such as cancer also remains to be investigated.
d-mannose treatment increased T reg cell frequencies and decreased numbers of IFN-γ-producing T effector cells in NOD mice compared with untreated controls. Although the beneficial effects of d-mannose in NOD mice were abrogated in the absence of T reg cells and TGF-β, the central role of this pathway in disease development and the limitations of the NOD experimental model do not allow us to dissect the extent to which T reg cells and TGF-β mediated d-mannose effects on diabetes in this study, and it is possible that d-mannose may act through additional mechanisms to suppress diabetes in vivo.
Notably, we replicated and confirmed this immunoregulatory effect of d-mannose in an ovalbumin-induced airway inflammation model, which indicates broader efficacy of mannose-mediated therapeutic effects on immunopathology. The notion that d-mannose treatment induces antigen-specific T reg cells and suppression of immunopathology was supported by this model of ovalbumin-induced airway inflammation.
The physiological level of d-mannose in the blood of humans and mice is approximately 100 µM. However, it has been reported that the amount of circulating d-mannose increases up to ninefold (from 100 to 900 µM) in mice receiving d-mannose in drinking water, with no adverse consequences 49 . Here we used the same amount of d-mannose as used in ref. 49 to supplement the drinking water in a r t i c l e s 1 0 4 4 VOLUME 23 | NUMBER 9 | SEPTEMBER 2017 nature medicine our in vivo experiments. In humans, stable serum d-mannose levels of up to 2 mM can be reached and are well tolerated, without signs of liver or renal toxicity 51 . We found that even concentrations of d-mannose as low as 1 mM could induce a considerable level of T reg cells, adding credence to the physiological significance of the findings. Moreover, the possible connection between the consumption of fruits rich in d-mannose (for example, cranberries) and autoimmunity may be an interesting and important issue. In sum, we have discovered a previously unrecognized immunoregulatory effect of d-mannose on T cells in both preventive and therapeutic models of type 1 diabetes and lung airway inflammation. Our findings warrant further exploration of the basic immunological mechanisms and potential clinical applications of hexose sugars.
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Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
